

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/378897798>

Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies

Article · March 2024

CITATIONS

0

READS

2

2 authors:



Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)

1,422 PUBLICATIONS 11,224 CITATIONS

SEE PROFILE



Getrude Uzoma Obeagu
Kampala International University (KIU)

384 PUBLICATIONS 3,307 CITATIONS

SEE PROFILE

Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²School of Nursing School, Kampala International University, Uganda

Abstract

Breast cancer and HIV coexistence presents a challenging medical landscape, necessitating a thorough exploration of hematologic considerations and blood transfusion strategies. This review delves into the intricate interplay of anemia, thrombocytopenia, neutropenia, and coagulopathy in breast cancer patients with HIV, offering insights into the management of these hematologic complications. Additionally, the article highlights key elements of blood transfusion strategies, treatment impacts, and infection risk mitigation in this unique patient population. A comprehensive understanding of these hematologic aspects is crucial for tailoring effective and patient-centered care, ultimately improving outcomes and enhancing the quality of life for individuals facing the dual burden of breast cancer and HIV.

Keywords: *Breast cancer, HIV, Hematologic considerations, Blood transfusion, Anemia, Thrombocytopenia, Neutropenia, Coagulopathy, Treatment strategies*

Introduction

Breast cancer and human immunodeficiency virus (HIV) represent formidable health challenges on a global scale, each demanding intricate medical management. In recent years, the intersection of these two conditions has emerged as a complex clinical scenario, garnering increased attention from researchers and healthcare professionals alike. The coexistence of breast cancer and HIV presents a multifaceted dilemma, where the interaction between these two diseases introduces unique hematologic considerations that significantly impact patient outcomes. The prevalence of breast cancer remains alarmingly high, affecting millions of women worldwide and posing substantial health and socioeconomic burdens. Concurrently, HIV, a viral infection that weakens the immune system, continues to be a global public health concern. As advancements in medical care have prolonged the lives of individuals with HIV, the overlap with other chronic conditions, such as cancer, has become increasingly prevalent. Breast cancer in the context of HIV introduces

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

new layers of complexity, demanding a comprehensive understanding of the hematologic manifestations and their implications for effective management.¹⁻²⁶

Anemia, thrombocytopenia, neutropenia, and coagulopathy emerge as key hematologic considerations in breast cancer patients with HIV. The intricate interplay of these factors, influenced by both the malignancy and the viral infection, necessitates a tailored and holistic approach to care. Understanding the dynamics of these hematologic complications is crucial for healthcare providers to deliver optimal treatment strategies, ensuring a balance between addressing the primary diseases and mitigating the potential complications arising from their intersection. Despite the growing awareness of the challenges posed by the dual burden of breast cancer and HIV, a comprehensive exploration of blood transfusion strategies in this specific population remains relatively limited. The transfusion of blood products plays a pivotal role in the supportive care of cancer patients, yet tailoring these strategies to the unique needs and complexities of breast cancer patients with HIV is a domain that requires deeper investigation. This review seeks to bridge this gap by providing insights into blood transfusion approaches that consider both the oncologic and HIV-related aspects, aiming to enhance the overall quality of care and patient outcomes in this distinctive cohort. As research in this field continues to unfold, a more nuanced understanding of hematologic considerations and blood transfusion strategies will undoubtedly contribute to refining the management of breast cancer patients with HIV, fostering improved therapeutic outcomes and patient well-being.²⁷⁻⁵⁰

Hematologic Considerations in Breast Cancer Patients with HIV

Breast cancer and human immunodeficiency virus (HIV) are two significant health challenges that, when coexisting, create a complex medical landscape with unique hematologic considerations. Breast cancer remains a leading cause of morbidity and mortality among women globally, while HIV, a viral infection causing immune system compromise, continues to affect millions worldwide. The convergence of these conditions raises critical questions about the impact on hematologic parameters and necessitates a comprehensive understanding of their interplay. One of the primary hematologic considerations in breast cancer patients with HIV is anemia. Both breast cancer and HIV can independently contribute to anemia, either through the chronic inflammation associated with cancer or the direct myelosuppressive effects of HIV on the bone marrow. Understanding the underlying causes of anemia in this dual-diagnosis population is crucial for devising effective management strategies and improving overall patient well-being.⁵¹⁻⁶⁵

Thrombocytopenia, characterized by low platelet counts, represents another hematologic challenge. Breast cancer treatments, particularly chemotherapy, and the immunosuppressive effects of HIV can synergistically contribute to a decreased platelet count, posing an increased risk of bleeding complications. Managing thrombocytopenia requires a delicate balance, considering both cancer and HIV-related factors to mitigate the potential risks. Neutropenia, a condition marked by a low absolute neutrophil count, further complicates the hematologic profile of breast cancer patients with HIV. Chemotherapy-induced myelosuppression, coupled with the

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

immunosuppressive nature of HIV, heightens the vulnerability to infections. Addressing neutropenia involves close monitoring of blood counts and implementing prophylactic measures to reduce the risk of severe infections. Coagulopathy, encompassing both prothrombotic and bleeding tendencies, emerges as an additional concern. Breast cancer itself can trigger alterations in coagulation pathways, and when compounded by the effects of HIV, the risk of thrombotic or hemorrhagic events may increase. Monitoring coagulation parameters becomes essential to strike a delicate balance between preventing thrombosis and avoiding bleeding complications.⁶⁶⁻⁸⁵

Blood Transfusion Strategies

Blood transfusion is a crucial component of supportive care for individuals undergoing breast cancer treatment, particularly when coexisting with human immunodeficiency virus (HIV). The intricate interplay of these two conditions introduces unique challenges that demand a nuanced approach to transfusion strategies. Setting individualized transfusion thresholds is fundamental in the management of breast cancer patients with HIV. Striking a balance between maintaining adequate hemoglobin levels and avoiding unnecessary transfusions is essential. Individual factors such as symptoms, overall clinical status, and the presence of comorbidities must be considered when determining the appropriate transfusion threshold. This personalized approach ensures that transfusion decisions are aligned with the specific needs of each patient. Understanding the impact of cancer treatments on hematologic parameters is crucial when establishing transfusion triggers. Chemotherapy-induced myelosuppression may necessitate a proactive approach to blood transfusions, especially during intensive treatment phases. Regular monitoring of hemoglobin levels and adjusting transfusion triggers based on the dynamic nature of cancer therapy contribute to a more responsive and effective transfusion strategy.⁸⁶⁻¹⁰²

Breast cancer patients with HIV are inherently immunocompromised, making infection risk mitigation a top priority in blood transfusion strategies. Rigorous screening of blood products for infectious agents, including HIV, is mandatory to prevent transfusion-related infections. Additionally, employing leukoreduction techniques helps minimize the risk of bacterial contamination and further enhances the safety of blood transfusions in this vulnerable patient population. Chronic blood transfusions can lead to iron overload, which may have implications for both breast cancer and HIV patients. Monitoring and managing iron levels in individuals undergoing repeated transfusions are critical to prevent complications such as organ damage. Coordinating with the oncology and HIV care teams to optimize transfusion strategies while mitigating iron-related risks ensures a comprehensive and patient-centered approach. Empowering breast cancer patients with HIV through education and involving them in shared decision-making regarding transfusion strategies are essential components of holistic care. Providing information about the rationale behind transfusion decisions, potential risks, and alternative approaches fosters patient engagement and enhances adherence to the recommended transfusion plan.¹⁰³⁻¹⁴⁸

Conclusion

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

The hematologic landscape in this population demands careful consideration of individualized transfusion thresholds, acknowledging the impact of cancer treatments, and prioritizing infection risk mitigation. By adopting a patient-centered approach, healthcare providers can optimize blood transfusion strategies, striking a delicate balance between maintaining hemoglobin levels and preventing unnecessary transfusions. Moreover, the management of iron overload, a potential consequence of repeated transfusions, necessitates close collaboration between oncology and HIV care teams. Monitoring and addressing iron-related risks contribute to a comprehensive care plan that prioritizes the overall well-being of individuals facing the dual burden of breast cancer and HIV. Empowering patients through education and shared decision-making further enhances the effectiveness of transfusion strategies. Providing insights into the rationale behind transfusion decisions, potential risks, and alternative approaches fosters patient engagement, improving adherence to recommended transfusion plans.

References

1. Mukerjee N, Maitra S, Ghosh A, Sengupta T, Alexiou A, Subramaniyan V, Anand K. Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics. *ACS Applied Nano Materials*. 2024.
2. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
3. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. *Medicine*. 2024 Jan 19;103(3):e36905.
4. Obeagu EI, Obeagu GU. Breastfeeding's protective role in alleviating breast cancer burden: A comprehensive review. *Annals of Medicine and Surgery*.:10-97.
5. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OP, Alum EU. Biomarkers of breast cancer: Overview. *Int. J. Curr. Res. Biol. Med.* 2023;1:8-16.
6. Obeagu EI, Obeagu GU. Breaking Ground: PARP Inhibitors and Their Efficacy in Breast Cancer Stages. *Elite Journal of Medicine*. 2024;2(2):42-54.
7. Obeagu EI, Obeagu GU. BRCA Mastery: Redefining Breast Cancer Care through Cutting-edge Diagnosis and Management. *Elite Journal of Medicine*. 2024;2(2):55-66.
8. Mohamed QH, Obeagu EI. Genetic Heterogeneity in Breast Cancer: Implications. *Elite Journal of Health Science*. 2024;2(1):20-4.
9. Mohamed AF, Obeagu EI. Genetic Influence on Breast Cancer Progression: A Molecular Perspective. *Elite Journal of Medica Science*. 2024;2(1):19-22.
10. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *Applied Sciences (NIJBAS)*. 2023;3(3).
11. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

12. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
13. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
14. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
15. Obeagu EI, Babar Q, Obeagu GU. Allergic blood Transfusion reaction: A Review. *Int. J. Curr. Res. Med. Sci.* 2021;7(5):25-33.
16. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):26-35.
17. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
18. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
19. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
20. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
21. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
22. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
23. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
24. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
25. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

- Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
26. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
 27. Borazanci E, Saluja A, Gockerman J, Velagapudi M, Korn R, Von Hoff D, Greeno E. First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity. *The Oncologist*. 2024;29(2):132-41.
 28. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
 29. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
 30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
 31. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-37.
 32. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Ugwu OP. Immunomodulatory Effects of Transfusions on Maternal Immunity in Pregnancy. *Applied Sciences (NIJBAS)*. 2023;3(3).
 33. Obeagu EI, Babar Q, Uduchi IO, Ibekwe AM, Chijioko UO, Okafor CJ, Vincent CC. An Update on Transfusion Related Immunomodulation (TRIM) in a Time of COVID-19 Pandemic. *Journal of Pharmaceutical Research International*. 2021 Aug 27;33(42A):135-146.
 34. Okoroiwu IL, Obeagu EI, Elemchukwu Q, Ochei KC, Christian GS. Frequency of Transfusion Reactions Following Compatible Cross Matching of Blood: A Study in Owerri Metropolis. *International Journal of Current Research and Academic Review*. 2015;3(1):155-160.
 35. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. *Int. J. Curr. Res. Med. Sci*. 2016;2(10):16-48.
 36. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
 37. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.59238/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf).
 38. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

2015;4(4):911-916.

https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.

39. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
40. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.iosronline.com/ViewFullText.aspx?doi=10.21961/iosrjpbs.120407)
41. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
42. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDA-AND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311811112_CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDA-AND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA).
43. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.researchgate.net/publication/358111112_Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu).
44. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
45. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/325444444_Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe)
46. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

47. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports*. 2023;6(8):e1450.
48. Obeagu EI, Ameorpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri*. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.1007/s12245-023-0139-1).
49. Obeagu EI, Scott GY, Ameorpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
50. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022:29-34.
51. Ogar CO, Okoroiwu HU, Obeagu EI, Etura JE, Abunimye DA. Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. *Transfusion Clinique et Biologique*. 2021;28(1):68-72.
52. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine*. 2023;102(47): e36342.
53. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. *EC Emergency Medicine and Critical Care*. 2020;4(7):33-40.
54. Obeagu EI, Buhari HA. Implications of Blood Transfusion in Renal Disease Patients. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(10):45-49.
55. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Ironi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. *Asian Hematology Research Journal*. 2022;6(3):9-17.
56. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
57. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.1007/s12245-022-0137-1).
58. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI:

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

- 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.ijarbs.com/links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
59. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134. DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.ijarbs.com/links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
60. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104. DOI: 10.22192/ijcrms.2017.03.05.014 [https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfecting with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
61. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
62. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
63. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183. DOI: DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.ijarbs.com/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
64. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
65. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
66. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine.* 2024;103(2): e36937.
67. Obeagu EI. An update on susceptibility of individuals to diseases based on ABO blood groups. *Int. J. Curr. Res. Med. Sci.* 2019;5(3):1-8.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

68. Eze R, Obeagu EI, Nwakulite A, Vincent CC, Ogbodo SO, Ibekwe AM, Okafor CJ, Chukwurah EF. Frequency of Haemoglobin Genotype Variants, ABO and Rh 'D' Antigen among Madonna Undergraduates of South East Origin, Nigeria. *Journal of Pharmaceutical Research International*. 2021 May 26;33(29B):149-57.
69. Okoroiwu IL, Obeagu EI, Christian SG, Elemchukwu Q, Ochei KC. Determination of the haemoglobin, genotype and ABO blood group pattern of some students of Imo State University, Owerri, Nigeria. *International Journal of Current Research and Academic Review*. 2015;3(1):20-27.
70. Oloro OH, Obeagu EI, Puche RO, Lawal OA. Blood Products in Blood Banking: Preparation and Clinical Importance. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(3):102-109.
71. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
72. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
73. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
74. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
75. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
76. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. <links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf>.
77. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
78. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

- 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://doi.org/10.22192/ijcreps.2019.06.12.004).
79. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.002).
80. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://doi.org/10.22192/ijcrms.2016.02.04.002).
81. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
82. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
83. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
84. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
85. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
86. Asemota EA, Njar VE, Aguanah IT, Obeagu EI. Distribution of ABO, Rhesus Blood Group and Helicobacter Pylori Infection among Secondary School Students in Calabar South Local Government, Cross River State, Nigeria. *Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035*. 2023;3(1):32-45.
87. Obeagu EI, Katya MC. A Systematic Review on Physiological Jaundice: Diagnosis and Management of the Affected Neonates. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):25-41.
88. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

89. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
90. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
91. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
92. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
93. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
94. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES).* 2023;3(2):56-59.
95. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
96. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
97. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
98. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
99. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
100. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
101. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

102. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
103. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
104. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
105. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
106. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
107. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
108. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023;10(10):56-62.
109. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
110. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
111. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
112. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024 Jan 12;103(2):e36937.
113. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
114. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
115. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

116. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024 Mar 1;103(9):e37354.
117. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
118. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;12(01)*.
119. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
120. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijar.com>;12(01)*.
121. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
122. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
123. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
124. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
125. Obeagu EI, Obeagu GU. The Crucial Involvement of CD8 in HIV Progression: A Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(2):15-25.
126. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
127. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
128. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
129. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
130. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
131. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

132. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
133. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>*;12(01).
134. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
135. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
136. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
137. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting Stigma: Essential Steps in Halting HIV Spread. *IAA Journal of Applied Sciences*. 2024;11(1):22-9.
138. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
139. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
140. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
141. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
142. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
143. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
144. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
145. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
146. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35

147. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
148. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):9-19.

Citation: Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*, 2024; 2(2): 20-35